StockData
InMed Pharmaceuticals Inc. logo

InMed Pharmaceuticals Inc. (MTRI) stock

MTRINasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as INM
Financials through Q1 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 4/30
$15.29−2.21 (-12.66%)

Close on Nov 18, 2026Market cap $83.97MP/E –Yield –

InMed Pharmaceuticals gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

InMed Pharmaceuticals's gross profit for the twelve months ending Dec 31, 2025 was $1.34M, down 21.7% year over year. For fiscal 2025 it was $1.71M, up 55.0% from the year before.

Annual gross profit

PeriodPeriod endValueChange
FY2025Jun 30, 2025$1.71M+55.0%
FY2024Jun 30, 2024$1.10M-21.5%
FY2023Jun 30, 2023$1.40M+158.1%
FY2022Jun 30, 2022$543.55K–

Quarterly gross profit

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q2 FY2026CQ4 2025Dec 31, 2025$184.19K-60.0%
Q1 FY2026CQ3 2025Sep 30, 2025$403.16K-18.3%
Q4 FY2025CQ2 2025Jun 30, 2025$576.65K+23.7%
Q3 FY2025CQ1 2025Mar 31, 2025$175.63K-39.3%
Q2 FY2025CQ4 2024Dec 31, 2024$460.89K+42.2%
Q1 FY2025CQ3 2024Sep 30, 2024$493.41K+2222.8%
Q4 FY2024CQ2 2024Jun 30, 2024$466.07K-70.3%
Q3 FY2024CQ1 2024Mar 31, 2024$289.46K+50.4%
Q2 FY2024CQ4 2023Dec 31, 2023$324.14K+147.1%
Q1 FY2024CQ3 2023Sep 30, 2023$21.24K–
Q4 FY2023CQ2 2023Jun 30, 2023$1.57M+528.9%
Q3 FY2023CQ1 2023Mar 31, 2023$192.51K+5.6%
Q2 FY2023CQ4 2022Dec 31, 2022$131.16K+17.6%
Q1 FY2023CQ3 2022Sep 30, 2022-$491.02K–
Q4 FY2022CQ2 2022Jun 30, 2022$249.71K–
Q3 FY2022CQ1 2022Mar 31, 2022$182.28K–
Q2 FY2022CQ4 2021Dec 31, 2021$111.56K–

More InMed Pharmaceuticals figures

See a number that looks wrong?